Literature DB >> 8446368

Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy.

C Baudouin1, D Fredj-Reygrobellet, F Brignole, F Nègre, P Lapalus, P Gastaud.   

Abstract

Mechanisms accounting for the development of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment remain poorly understood. In a previous study, we found the presence of various growth factors in preretinal membranes that were surgically removed from patients with PVR. The present immunohistological study was undertaken in intravitreal and subretinal fluid cells from patients suffering from PVR in various stages of development, in order to seek the presence of 4 growth-promoting factors for retinal pigment epithelial cells: acidic fibroblast growth factor (FGF), epidermal growth factor (EGF), insulin-like growth factor type I (IGF-I) and transforming growth factor-beta (TGF-beta). Results were quite similar in vitreous and subretinal fluid. Acidic FGF was found in all vitreous and subretinal specimens, in 30-100% of the examined cells. Immunoreactivity for EGF could be found in 53% of intravitreal cells and 69% of subretinal fluid cells. Positive cells were seen in all vitreous specimens and in all but 1 of the subretinal fluid specimens. IGF-I-containing cells were present in 13 of 15 vitreous specimens and in 18 of 20 subretinal fluid samples (mean percentages of reactivity in positive specimens 70% and 78%, respectively). In contrast, TGF-beta 1 reactivity was found in only 8 of 15 vitreous specimens and in 11 of 20 subretinal samples. Mean percentages of reactive cells were 30% and 50%, respectively. These results suggest that several growth factors could be involved in the proliferation and migration of retinal pigment epithelial cells during the course of PVR.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8446368     DOI: 10.1159/000267221

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  36 in total

1.  The effects of pleiotrophin in proliferative vitreoretinopathy.

Authors:  Xue Ding; Yujing Bai; Xuemei Zhu; Tianqi Li; Enzhong Jin; Lvzhen Huang; Wenzhen Yu; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-12       Impact factor: 3.117

2.  Growth factors outside the PDGF family drive experimental PVR.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Debra Gilbertson; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-25       Impact factor: 4.799

3.  [Vitreal-induced RPE cell traction. Investigation of pathological vitreous samples in an in vitro contraction model].

Authors:  J Beutel; M Lüke; K-U Bartz-Schmidt; S Grisanti
Journal:  Ophthalmologe       Date:  2009-10       Impact factor: 1.059

4.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

Review 5.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

6.  Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses.

Authors:  Steven Pennock; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2012-03-19       Impact factor: 4.272

7.  A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Authors:  Steven Pennock; Marc-Andre Rheaume; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2011-10-28       Impact factor: 4.307

8.  Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells.

Authors:  Hetian Lei; Marc-André Rhéaume; Gisela Velez; Shizuo Mukai; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-24       Impact factor: 4.799

9.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

Review 10.  Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.

Authors:  Hetian Lei; Marc-Andre Rheaume; Andrius Kazlauskas
Journal:  Exp Eye Res       Date:  2009-11-25       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.